Biogen, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $692.9M | 118,541 | 80.5% |
| Royalty or License | $63.2M | 186 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44.8M | 15,648 | 5.2% |
| Consulting Fee | $34.7M | 9,496 | 4.0% |
| Grant | $13.5M | 389 | 1.6% |
| Food and Beverage | $6.4M | 272,248 | 0.7% |
| Travel and Lodging | $5.2M | 20,579 | 0.6% |
| Education | $165,200 | 5,595 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | $89.9M | 50 | 36,622 |
| 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | $68.9M | 2 | 26,681 |
| A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 | $56.1M | 2 | 209 |
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | $38.6M | 34 | 1,493 |
| A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease | $37.8M | 0 | 260 |
| Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 | $23.9M | 0 | 108 |
| A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies. | $21.1M | 3 | 342 |
| Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 | $16.4M | 0 | 210 |
| An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational Studies of ISIS 396443 | $15.3M | 0 | 52 |
| A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety,Tolerability, and Pharmacokinetics of BIIB105 Administered Intrathecally to AdultsWith Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in theAtaxin-2 Gene | $13.3M | 0 | 42 |
| Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | $10.6M | 36 | 1,722 |
| Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | $10.2M | 7 | 76 |
| Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | $9.9M | 28 | 2,744 |
| Long-Term Evaluation of BIIB067 | $8.9M | 3 | 396 |
| Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) Demonstration Project | $8.6M | 16 | 289 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration | $7.6M | 0 | 100 |
| Multi-center, randomized, double-blinded assessment of Tecfidera in extending the time to a first attack in radiologically isolated syndrome (RIS) | $7.5M | 0 | 4 |
| Study of BIIB092 in Participants With Progressive Supranuclear Palsy | $6.9M | 9 | 399 |
| Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease | $6.8M | 3 | 4,009 |
| Dimethyl Fumarate (DMF) Observational Study | $6.6M | 2 | 17,457 |
| An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect of Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation | $6.3M | 1 | 57 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | $6.2M | 15 | 563 |
| A Randomized, Double-Blind, Parallel-Group, Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of BIIB800 s.c. compared to the Reference Product Actemra® in Healthy Subjects | $5.6M | 0 | 4 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | $5.3M | 80 | 887 |
| A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | $5.2M | 6 | 118 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment | $5.1M | 0 | 74 |
| A prospective, multi-center, open-label, observational study of the safety, tolerability and effectiveness of SPINRAZA in adults with SMA | $5.1M | 0 | 7 |
| An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | $5.0M | 23 | 143 |
| A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension | $4.9M | 5 | 64 |
| A 2-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vixotrigine (BIIB074) Following Multiple Oral Doses at Therapeutic and Supratherapeutic Dose Levels (Part 1), and a Randomized, Double-Blind, Placebo- and Positive-Controlled (Moxifloxacin), Parallel Study with a Nested Crossover to Assess the Effect of Multiple Oral Supratherapeutic Doses of Vixotrigine on Cardiac Repolarization (Part 2) in Healthy Subjects | $4.1M | 0 | 9 |
Payments by Medical Specialty
Top Paid Doctors — Page 1319
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Amarish Dave, Do, DO | Neurology | Woodstock, IL | $10.55 | $0 |
| Dr. Hemang Shah, Mbbs, MBBS | Internal Medicine | Burlington, NC | $10.55 | $0 |
| Jacob Kaufman, Md, MD | Neurology | Nashua, NH | $10.55 | $0 |
| Dr. Lisa Aenlle, Md, Mph, MD, MPH | Neurology | Naples, FL | $10.53 | $0 |
| Dr. Timothy Adams, Md, MD | Internal Medicine | Bozeman, MT | $10.53 | $0 |
| Stuart Kieran, Md, MD | Neurology | Boca Raton, FL | $10.49 | $0 |
| Martin Solomon, Md, MD | Neurology | Grapevine, TX | $10.49 | $0 |
| Dr. Linh Dang, M.d, M.D | Student in an Organized Health Care Education/Training Program | Houston, TX | $10.48 | $0 |
| Michael Pietak, M.d, M.D | Internal Medicine | Durham, NC | $10.40 | $0 |
| Robert Gross, M.d, M.D | Neurology | Aurora, CO | $10.36 | $0 |
| Jeffrey Bennett, Md, MD | Neurology | Aurora, CO | $10.36 | $0 |
| Marcia Dover, Md, MD | Neurology | Dover, NJ | $10.31 | $0 |
Top Products
- ADUHELM $122.8M
- SPINRAZA $68.5M
Associated Products (19)
- ADUHELM $122.8M
- SPINRAZA $68.5M
- TYSABRI $44.4M
- TECFIDERA $34.7M
- VUMERITY $15.7M
- PLEGRIDY $5.9M
- TOFIDENCE $5.6M
- SKYCLARYS $4.5M
- QALSODY $2.9M
- ZINBRYTA $2.8M
- AVONEX $1.9M
- Tysabri $1.3M
- Vumerity $800,534
- Spinraza $566,008
- Skyclarys $506,883
- Zurzuvae $37,633
- LEQEMBI $30,230
- Plegridy $30,209
- BYOOVIZ $18,213
Payment Categories
- Food & Beverage $6.4M
- Consulting $34.7M
- Travel & Lodging $5.2M
- Research $692.9M
- Royalties $63.2M
About Biogen, Inc.
Biogen, Inc. has made $860.9M in payments to 32,962 healthcare providers, recorded across 442,682 transactions in the CMS Open Payments database. In 2024, the company paid $53.8M. The top product by payment volume is ADUHELM ($122.8M).
Payments were distributed across 255 medical specialties. The top specialty by payment amount is Neurology ($57.6M to 6,752 doctors).
Payment categories include: Food & Beverage ($6.4M), Consulting ($34.7M), Research ($692.9M), Travel & Lodging ($5.2M), Royalties ($63.2M).
Biogen, Inc. is associated with 19 products in the CMS Open Payments database, including ADUHELM, SPINRAZA, and TYSABRI.